JP Morgan Chase
SNDX icon

JP Morgan Chase’s Syndax Pharmaceuticals SNDX Stock Holding History

JP Morgan Chase’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,900
Closed -$395K – 7694
2024
Q4 		$395K Sell
29,900
-4,300
-13% -$73.6K ﹤0.01% 5158
2024
Q3 		$658K Hold
34,200
– – ﹤0.01% 4739
2024
Q2 		$702K Hold
34,200
– – ﹤0.01% 4494
2024
Q1 		$814K Buy
+34,200
New +$763K ﹤0.01% 4488
2023
Q4 		– Sell
-125,000
Closed -$1.81M – 7848
2023
Q3 		$1.81M Buy
+125,000
New +$2.36M ﹤0.01% 3610

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

JP Morgan Chase's SNDX Position: Q2 2026 in Review

JP Morgan Chase reduced its Syndax Pharmaceuticals (SNDX) stake by 10% in Q2 2026, selling an estimated $563K and leaving 231,446 shares worth $5.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

JP Morgan Chase first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. The position peaked at $16.9M in Q4 2023. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • JP Morgan Chase held 231,446 shares of Syndax Pharmaceuticals worth $5.13M as of Q2 2026.
  • JP Morgan Chase sold 27,073 Syndax Pharmaceuticals shares in Q2 2026, an estimated $563K.
  • Syndax Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3429 holding.
  • JP Morgan Chase first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • JP Morgan Chase's Syndax Pharmaceuticals position peaked at $16.9M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.